Patent Application
20120251586
The invention relates generally to the field of immunology. More particularly, the invention relates to protecting biomaterials from immune cell-mediated damage, especially when the biomaterials are implanted into the body of an animal.
Various publications, including patents, published applications, technical articles and scholarly articles are cited throughout the specification. Each of these cited publications is incorporated by reference herein, in its entirety and for all purposes.
Material degradation of implantable polyurethane (PE) containing devices, as a result of chronic inflammation, remains an important problem in biomaterials research. Reactive oxygen species (ROS) released from adherent monocyte-derived macrophages (MDMs) play a role in the structural damage observed in PE-containing vascular implants such as pacemaker lead insulation (Schubert, M A et al. (1997) J. Biomed. Mater. Res. 34:519-30; Labow, R S et al. (2002) Biomaterials 23:3969-75; and, Santerre, J P et al. (2005) Biomaterials 26:7457-70). Modifying bulk preparations of PE with phenol-based anti-oxidants effectively reduces the ROS mediated damage to PE films, but is limited by the fact that the anti-oxidant capacity is expended after reacting with the oxygen radical (Stachelek, S J et al. (2006) J. Biomed. Mater. Res. A. 78:653-61; Stachelek, S J et al. (2007) J. Biomed. Mater. Res. A. 82:1004-11; Schubert, M A et al. (1996) J. Biomed. Mater. Res. 32: 493-504; and, Schubert, M A et al. (1997) J. Biomed. Mater. Res. 34:493-505).
Previous attempts to inhibit immune cell activation have largely used a co-blending strategy to modify the PE surface by adding to it molecules such as polyethylene oxide (PEO), polypropylene oxide (PPO) or tri-block fluorinated macromolecules with the idea that the surface-oriented molecules will reduce protein adsorption (Massa, T M et al. (2007) J. Biomed. Mater. Res. A. 81:178-85; Ward, R et al. (2007) J. Biomed. Mater. Res. A. 80:34-44; and, Ebert, M et al. (2005) J. Biomed. Mater. Res. A. 75:175-84). Although these co-blending strategies did indeed reduce the levels of MDM activation, co-blending as a delivery strategy is limited, in part, because co-blending is inefficient, as not all the therapeutic molecules will be oriented on the PE film surface where it is needed; and, co-blending alters the physical properties of the PE film.
There exists a need in the art for more efficient protection of biomaterials which does not alter the physical properties of the biomaterials.
The invention provides methods for protecting biomaterials and for inhibiting or preventing immune cell attachment to biomaterials. In general, the methods comprise attaching CD47 or Ig domain thereof to the surface of a biomaterial. The CD47 or Ig domain thereof protects biomaterials by inhibiting or reducing immune cell attachment and/or immune cell-mediated damage to the biomaterial. The methods can be used to inhibit or reduce immune cell attachment or immune cell-mediated damage to biomaterial in vitro and in vivo.
The invention also provides biomaterials protected from immune cell attachment and/or immune cell-mediated damage to the biomaterials. For example, a protected biomaterial comprises CD47 or Ig domain thereof attached to the surface of the biomaterial. The biomaterial further comprises at least one linking molecule on the surface of the biomaterial. The linking molecule mediates the attachment of the CD47 or Ig domain thereof to the surface.
Preferred biomaterials comprise a polymer such as a polypropylene, polyethylene, polystyrene, polymethylmethacrylate, polyurethane, polyfluorotetraethylene, or polyvinyl, or mixtures thereof. The methods can be used to protect biomaterials in an implant, catheter, medical device, tube, or therapeutic agent delivery vehicle, among other things. Thus, implants, catheters, medical devices, tubes, or therapeutic agent delivery vehicles can comprise one or more biomaterials, and/or can be coated with one or more biomaterials.
The surface of the biomaterial can be modified to comprise at least one linking molecule to mediate interaction of the biomaterial with CD47 or Ig domain thereof. In addition, the CD47 or Ig domain thereof can be complexed with at least one linking molecule to mediate its interaction with the biomaterial or a linking molecule on the biomaterial. Examples of linking molecules include avidin, biotin, thiol, folate, the folate receptor, SPDP, and SMCC.
The described methods can be used to protect biomaterials from any immune cell attachment or damage induced by any immune cell. Preferably, the immune cell expresses SIRP-α. Exemplary immune cells include monocytes and macrophages, as well as polymorphonuclear cells, for example, neutrophils. The damage inhibited or reduced by the inventive methods is directly related to the inflammatory response, such as, but not limited to cytokines, reactive oxygen species, or hydrolytic enzymes released by immune cells that can have a deleterious effect upon the host and/or the implanted biomaterial.
The invention also provides kits for protecting biomaterials. Generally, the kits comprise CD47 or the Ig domain thereof and instructions for using the kit in a method to protect biomaterials and/or a method to inhibit or reduce immune cell attachment to biomaterials. The kits can comprise one or more linking molecules capable of being attached to the surface of the biomaterial or to CD47 or Ig domain thereof. Examples of linking molecules include avidin, biotin, thiol, folate, the folate receptor, SPDP, and SMCC. The CD47 or Ig domain thereof can be pre-complexed with a linking molecule.
It has been observed in accordance with the present invention that CD47 is capable of conferring protection to biomaterials against damage caused by immune cells by means of utilizing the CD47-SIRPα pathway. The feasibility of passivating polyurethane and polyvinyl chloride surfaces with the Ig domain of CD47 was investigated as a means of reducing the inflammatory response initiated against such biomaterial polymers. Accordingly, the embodiments of the invention provide methods for protecting a biomaterial. In general, the methods comprise attaching CD47, the Ig domain thereof, or other suitable domain or subdomain thereof, to the surface of a biomaterial, wherein the CD47, Ig domain, or subdomain thereof inhibits or reduces immune cell-mediated damage to the biomaterial.
Signal regulatory protein alpha (SIRP-α) is a potential signaling protein found in MDMs that may be targeted to confer immunoresistance to implantable biomaterials. SIRP-α is a transmembrane protein expressed by MDMs and other cells of myeloid origin. SIRP-α signaling is mediated by tyrosine inhibitory motifs (ITIMs) located in the cytoplasmic tail of SIRP-α. The SIRP ITIMs activate Src homology domain 2-containing phosphatases-1 (SHP-1) and (SHP-2). Recruitment and activation of SHP-1 and SHP-2 by SIRP-α negatively regulates phagocytosis by macrophages (van Beek, E M et al. (2005) J. Immunol. 175:7781-7). SIRP-α may also be identified as CD172A, SHPS1, P84, MYD-1, BIT, PTPNS1 or SIRP-1α.
CD47, also known as integrin associated protein, is a ubiquitously expressed transmembrane protein. It is a member of the immunoglobulin (Ig) superfamily of membrane proteins with a single, variable Ig domain at its N terminus. The Ig domain of CD47 has been recently identified as a ligand of SIRP-α (Brown, E J et al. (2001) Trends Cell Biol 11:130-5; Vernon-Wilson, E F et al. (2000) Eur. J. Immunol. 30:2130-7; Takizawa, H et al. (2007) Nat. Immunol. 8:1287-9; and, Subramanian, S et al. (2006) Blood 107:2548-56). Additional studies have shown that SIRP-α binding to CD47 prevents phagocytosis of CD47 immobilized microbeads and red blood cells, in a species specific manner, by MDMs (Subramanian, S et al. (2006) Blood 107:2548-56; Oldenborg, P A (2004) Leuk, Lymphoma 45:1319-27; Tsai, R K et al. (2008) J. Cell Biol. 180:989-1003; Oldenborg, P A et al. (2000) Science 288:2051-4; and, Okazawa, H et al. (2005) J. Immunol. 174:2004-11). Furthermore, it has been shown that a CD47 homologue expressed in Myxoma virus contributes to the downregulation of MDM activation (Cameron, C M et al. (2005) Virology, 337:55-67). The Ig domain of the CD47 protein is highly variable between species. It has been reported that this variability affects the binding affinity between SIRP-α and CD 47 (Subramanian, S. et al. (2007) J. Biol. Chem. 282(3):1805-18).
The methods described and exemplified herein are suitable for protecting any biomaterial. Biomaterials include any materials suitable for biological, biomedical, or medical applications. Non-limiting examples of biomaterials include fabrics, ceramics, polymers, thermoplastics such as polyaryletherketone and polyetherketoneketone, adhesives, bone cement, metals, and the like. Polymers are most preferred. Biomaterial polymers include, without limitation, polypropylene, polyethylene, polyester, polystyrene, polymethylmethacrylate, polyurethane, polyfluorotetraethylene, or polyvinyl, polyethyleneimine, polyamide, polyacrylonitrile, polyacrylate, polymetacrylate, polyorthoester, polyether-ester, polylactone, polyalkylcyanoacrylate, polyethylenvinyl acetate, polyhydroxybutyrate, polytetrafluoroethylene, polyethylene terephthalate, polyoxyethylene, and the like, or mixtures thereof. Highly preferred polymers include polyurethane and polyvinyl chloride.
Biomaterials are used in various biological, biomedical, or medical applications. Such applications include the make-up of compositions, products, and devices such as artificial joints, implants, stents, dental implants, bone cement, catheters, tubes, artificial tendons and ligaments, artificial skin, artificial heart valves, delivery vehicles for therapeutic agents, particles, and the like. In preferred aspects, the methods are applicable to protect the biomaterials used to fabricate these compositions, products, and devices and/or biomaterials coated onto the surface of these compositions, products, and devices. Thus, in preferred aspects, the methods are applicable to protect compositions, products, and devices comprising biomaterials. Preferably, the methods are used to protect implants, tubes, catheters, and therapeutic agent delivery vehicles comprising biomaterials. More preferably, the methods are used to protect leads of a cardiac pacemaker comprising biomaterials and tubes comprising biomaterials that carry blood between a patient and a heart-lung bypass machine.
CD47 plays a role, among other things, in cell adhesion to the extracellular matrix in vivo, and also serves as a receptor for the C-terminal domain of thrombospondin. CD47 is also believed to play a role in cellular signal transduction. The described methods can utilize CD47, or any isoform thereof. The methods of the invention can also utilize the any suitable subdomain of CD47, including the extracellular Ig domain or subdomain thereof. Suitable subdomains of CD47 or its Ig domain preferably will be those that are capable of binding to or otherwise interacting with SIRP-α or any other ligand on an immune cell that signals the immune cell not to activate or produce biomaterial-damaging agents such as reactive oxygen species.
The CD47, Ig domain, or other suitable subdomain thereof can be from any species, including mouse, rat, rabbit, horse, pig, sheep, cow, cat, dog, human and the like. Porcine, bovine and human CD47 are particularly preferred.
Biomaterials can be modified to reduce or inhibit immune cell attachment and/or immune cell-mediated damage to the biomaterials. For example, a modified biomaterial comprises CD47 or Ig domain thereof attached to the surface of the biomaterial.
The methods are suitable to inhibit or reduce immune cell-mediated damage to biomaterial in vitro, for example, biomaterials used in cell culture or in experiments generally. The methods are also suitable to inhibit or reduce immune cell-mediated damage to the biomaterial in vivo, for example, biomaterials permanently or temporarily implanted, administered to, inserted, or otherwise inside of an animal.
The CD47, Ig domain, or suitable subdomain thereof can be attached to the biomaterial according to any means suitable in the art. For example, the CD47, Ig domain, or suitable subdomain thereof can be mixed with the biomaterial during manufacture of a composition, product, or device comprising the biomaterial such that the CD47, Ig domain, or suitable subdomain thereof is interspersed throughout the biomaterial, including on the surface of the particular composition, product, or device produced from the biomaterial. In some aspects, the CD47, Ig domain, or suitable subdomain thereof can be attached to the biomaterial, for example, by non-covalent intermolecular attractions, or by ionic or covalent bonds between the biomaterial and the CD47, Ig domain, or suitable subdomain thereof.
In some preferred aspects, the CD47, Ig domain, or suitable subdomain thereof can be attached to the biomaterial by way of linking molecules. The linking molecules can be complexed or conjugated to the biomaterial and/or the CD47, Ig domain, or suitable subdomain thereof. Linking molecules are any molecules capable of mediating or facilitating the attachment of the CD47, Ig domain, or suitable subdomain thereof to the biomaterial. Linking molecules can be any organic or inorganic chemical, proteins, polypeptides, polynucleotides, polysaccharides, lipids, thiols, and the like. Linking molecules are known in the art, and can be selected according to the needs of the practitioner. Some non-limiting examples of linking molecule pairs include avidin or streptavidin and biotin, thiol and Succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) or Succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC), or suitable variants or isoforms thereof, and folate and the folate receptor.
Thus, in some preferred aspects, CD47 can be prepared comprising thiol-reactive groups via reacting NH2 of its lysine residues with bifunctional amino- and thiol-reactive cross-linkers such as SPDP (as shown in
The inventive methods protect biomaterials from damage induced or exacerbated by immune cells. Preferably, the methods protect biomaterials from damage induced or exacerbated by polymorphonuclear cells, including neutrophils, basophils, and eosinophils, peripheral blood mononuclear cells, including monocytes, and/or macrophages. In some aspects, the methods protect biomaterials from damage induced or exacerbated by immune cells that express a ligand or receptor for CD47, such as SIRP-α. In some aspects, the methods can protect against an immune cell response caused by cis-acting CD47-SIRP-α mechanisms, elicited by the CD47 molecular interactions with SIRP-α molecules that are both expressed in the same cell. The methods can protect against any damage induced or exacerbated by immune cells, and preferably protect against oxidative damage, such as the damage to the biomaterial caused by exposure to reactive oxygen species and radicals produced by immune cells. The methods can also protect against inflammatory molecules, cytokines and/or hydrolytic enzymes produced by immune cells.
Embodiments of the invention include kits for protecting biomaterials utilizing the methods described and exemplified herein. In some aspects, the kits comprise CD47, the CD47 Ig domain, or subdomain thereof, and instructions for using the kit in a method for protecting a biomaterial. In some aspects, the kits further comprise one or more linking molecules capable of being attached to the surface of a biomaterial, and/or capable of being attached to the CD47, the CD47 Ig domain, or subdomain thereof, and may further comprise reagents suitable for attaching the linking molecule to the CD47, Ig domain, or subdomain thereof. In some aspects, the CD47, Ig domain, or subdomain thereof is complexed with a linking molecule. In some detailed aspects, the CD47, Ig domain, or subdomain thereof is complexed with SPDP or SMCC. In some detailed aspects, the CD47, Ig domain, or subdomain thereof is complexed with biotin. In some detailed aspects, the CD47, Ig domain, or subdomain thereof is complexed with folate. In some detailed aspects, the CD47, Ig domain, or subdomain thereof is complexed with the folate receptor.
The following examples are provided to describe exemplary aspects of the invention in greater detail. They are intended to illustrate, not to limit, the invention.
To begin to assess the contribution of the SIRPα/CD47 pathway in MDM attachment to PE surfaces, cells of the MDM cell line (THP-1) were transduced with the addition of 1.6×10−7 M of phorbol 12 myristate 13-acetate (PMA) to the media and were cultured on PE films in the presence of increasing concentrations (0, 2.5, 5, 10 μg) of anti-SIRP-α antibody directed against the protein's extracellular domain. Cells were allowed to attach to the PE films for 48 hours, at which time the films were washed with PBS and the remaining cells were fixed with 4% paraformaldehyde and stained with the nuclei specific stain DAPI.
Cell retention was determined by DAPI staining and counting the 9 separate 200× fields. As shown in
In the initial studies, biotinylated CD47 of human origin (hCD47) was appended to avidin-immobilized films, as shown in
Biotinylated CD47 was immobilized to the PE surface by applying PDT-BzPh as a micelle suspension. Under UV-irradiation, BzPh groups form covalent bonds with PE macromolecules. PDT groups on the PE films are then reduced to thiol-groups by reacting with a solution of TCEP. Avidin (10 mg/ml) was reacted with SPDP and purified by passing through a Sephadex® (GE Healthcare Bio-Sciences AB LLC, Uppsala Sweden) column. PE films were reacted with the thiol reactive avidin and incubated overnight at room temperature. The avidin-immobilized films were then washed 5 times in dH2O and increasing concentrations (3.9 ng, 7.8 ng, 15.62 ng, 31.25 ng, 62.5 ng, 125 ng, 250 ng, and 500 ng) of biotinylated CD47 (see below for details) were added to each film.
To assess the immobilization of CD47 on the PE surface, a control film and avidin-crosslinked films were incubated with mouse anti-CD47 antibody (B6H12 directed against the extracellular domain of human CD47). The antigen antibody complex was detected by incubation with a FITC-conjugated mouse secondary antibody. The immune complex was visualized using fluorescent microscopy and a FITC filter set.
A representative fluorescent photomicrograph shows robust fluorescence (
Source of biotinylated CD47. Plasmids encoding the extracellular domain of hCD47 were PCR amplified and ligated in frame with the vector pEF-BOS-XB which formed the in frame fusion of CD4d3+4 biotin at the C-terminus of the extracellular domain of CD47. This construct was transfected into CHO (−K1) cells and the secreted CD47-CD4d3+4 was concentrated, biotinylated at the C-terminus, and dialyzed. The protein was affinity purified using a monomeric avidin and dialyzed against PBS.
PMA-activated THP-1 cells (100,000 cells) were seeded on 1 cm2 PE-CD47 (over a range of CD47 concentrations) and control films. PE-CD47 films were prepared with biotinylated hCD47 as described in Example 2. Cells were allowed to attach to the PE films for 48 hours, at which time the films were washed with PBS and remaining cells were fixed with 4% paraformaldehyde and stained with the nuclei-specific stain DAPI. Cell retention was determined by DAPI staining and counting 9 separate 200× fields.
At the lowest CD47 surface concentration (˜10 molecules/μm2) there was significant (p<0.001) reduction of THP-1 cell attachment (24.6±8.2 cells/200× field) compared to unmodified control surfaces (131.23±21.6 cells/200× field). There was a further four-fold reduction in THP-1 attachment to PE-CD47 surfaces at CD47 concentrations between 80-301 molecules/μm2. Cell attachment was virtually abolished at CD47 concentrations greater than 600 molecules/μm2. These data show that immobilized CD-47 on PE reduced monocyte attachment and provide proof of principal for the feasibility of establishing a biomimetic PE surface with immobilized CD 47 molecules.
Studies were conducted to determine if surface immobilized, recombinant human CD47 (biotinylated) can inhibit neutrophil adhesion to polyvinyl chloride (PVC) surfaces.
Briefly, cells cultivated from the human neutrophil cell line, HL-60, were suspended at a concentration of approximately 1.5×106 cells/ml in growth media supplemented with 5 μg/ml of IgG and the phorbol ester, phorbol 12-myristate 13-acetate (PMA). The resuspended cells were added to uncoated (control) PVC tubing or PVC tubing that was modified by immobilizing CD47 (via avidin-biotin affinity) on the surface of the tubing, or with a coating of avidin alone (avidin control). The tubes containing the cells were capped at both ends and shaken for 3 hours at 37° C. After this incubation period, the cell media containing unbound cells was removed, the tubing was washed 4× with PBS, and attached cells were fixed by the addition of 4% paraformaldehyde. Cells attached to the PVC tubing were quantified by staining with the fluorescent dye DAPI (blue color on fluorescent micrographs) and visualized using a fluorescent microscope with the appropriate filter set.
Fluorescent micrographs of the cells attached to PVC tubing are shown in
These results strongly suggest that CD47 immobilized on the surface of a biomaterial polymer can reduce or prevent the acute inflammatory response caused by polymorpholeukocyte attachment to PVC tubing, a typical tubing used in cardiopulmonary bypass systems.
The Chandler loop is an apparatus in which a moving column of blood (or suspended cells in culture) flows in a circular closed tubing loop that is rotated on a slanted, electrically driven turntable. Investigations involving the simulation of blood flow within a cardiopulmonary bypass (CPB) circuit often use the Chandler loop. In this Example, the Chandler loop was used to investigate the effects of CD47 toward protecting PVC surfaces from whole blood under simulated blood flow conditions.
Briefly, 10 ml of whole human blood were freshly drawn (IRB-approved protocol), supplemented with sodium citrate to inhibit clotting, and introduced to a Chandler loop prepared from PVC tubing (approximately 33 cm in length) which was either surface modified with immobilized CD47 (biotinylated) or unmodified (no CD47, and no avidin (control)). The tubing was rotated for three hours at 37° C., with resulting circulation of the blood within the loop. At the end of the protocol, the blood was removed, and the tubing was washed with phosphate buffered saline. Attached cells were fixed with 4% paraformaldehyde.
Five segments of tubing (approximately 3 cm long), located at regular intervals along the length of the tubing, were excised, and any attached cells were quantified by staining with the fluorescent dye DAPI (blue color on fluorescent micrographs) and visualized using a fluorescent microscope with the appropriate filter set. The results are shown in
These data obtained with fresh whole human blood support the data shown in Example 4 obtained from using the neutrophil cell line HL-60 cells. In addition, these results show that the anti-inflammatory properties of surface bound CD47 on PVC tubing are fully functional in a model that approximates the cardiopulmonary bypass circuit, which is one example of a clinical application for this technology.
This is a prophetic example.
Cracking of explanted pacemaker lead insulation has been widely noted (Wiggins, M J et al. (2001) J. Biomed. Mater. Res. 58:302-7; and, Sutherland, K et al. (1993) J. Clin. Invest. 92:2360-7). Efforts to model this in vivo have largely relied upon the rat subdermal implant model, which is a useful and cost effective in vivo model to screen CD47-containing PE variants for resistance to oxidative degradation (Schubert, M A (1996) J. Biomed. Mater. Res. 32:493-504; Schubert, M A et al. (1997) J. Biomed. Mater. Res. 34:493-505; and, Stachelek, S J et al. (2007) J. Biomed. Mater. Res. A 82:1004-11. However, PE degradation has never been studied in an in vivo model of transvenous pacer lead implantation.
Lead formulations of CD47-modified PE will be examined in a right sided transvenous implant model. The rationale for this model is as follows: 1. The transvenous implant is a clinically relevant model approximating the use of PE as a cardiac pace maker lead insulation used clinically. 2. The transvenous implant allows in vivo examination of the effects of a blood-contacting environment upon host inflammatory response to implanted PE.
A clinical application for antioxidant modified PE will be simulated by implanting PE tubing±a candidate CD47 modification into porcine jugular veins for durations up to 10 weeks. With regard to oxidative degradation, it has been reported that 10 weeks in vivo corresponds to 2 week exposure in the solution of H2O2 CoCl2 (Christenson, E M et al. (2004) J. Biomed. Mater. Res. A. 70:245-55; and, Christenson, E M et al. (2004) J. Biomed. Mater. Res. A. 269:407-16).
In brief, castrated male or non-pregnant female swine (Yorkshire Cross) will be anesthetized and intubated. A cut down to the jugular vein will allow the placement of PE tubing, whereupon it will be secured in the vein and the remaining portion will be secured in a loop and placed in a subcutaneous pocket.
Explant analysis. At the termination of the study, the animal will be euthanized following standard operating procedures. Leads will be explanted and shipped overnight for further analysis at the Children's Hospital of Philadelphia. Half of the length of the tubing will be processed for changes in the mechanical-physical properties as a result of implantation. The remaining half will be processed for biologically relevant endpoints.
Mechanical-Physical Properties. Explanted tubing will be washed in a detergent solution to remove biological debris. Soft segment chain scission and loss will be assessed via FTIR analysis. SEM will provide qualitative assessment of damage to the implanted PE surface. Uniaxial stress-strain tests will also be performed to determine any loss of elasticity as result of implantation.
Biological Endpoints. Half of the explanted tubing will be placed in formalin and assessed for relevant biological endpoints. Giemsa staining will be used to identify cell types that are present on the explanted PE tubing. DAPI staining will be used to quantify cell numbers on the explanted PE surfaces. Proteins of interest will be identified via immunofluorescence microscopy. These biological endpoints will correlate with the mechanistic endpoints as well as with the results obtained from initial in vivo studies of subdermal implants in rats.
Studies were carried out to compare the efficacy of immobilized CD47, of human (hCD47) or bovine (bCD47) origin, upon MDM binding to polyurethane (PU) surfaces. As described in Example 3, PU films were similarly modified with hCD47 or bCD47. PMA activated THP-1 cells were cultured on modified PU film surfaces. Where indicated the modified films were preincubated with anti-human CD47 antibody B6H12. Shown in
Rat subdermal implant model has been utilized as an in vivo model to investigate chronic inflammatory effects upon implanted biomaterials (Stachelek, S J et al. (2007) J. Biomed. Mater. Res. A 82(4):1004-11). Similar to the PE degradation study described in Example 6, cracking studies of polyurethane (PU) subdermal implants were carried out in rats.
All procedures and animal husbandry were in compliance with NIH standards pertaining to the care and use of laboratory animals as approved by the IACUC of the Children's Hospital of Philadelphia. Each of the five rats per group received three 1 cm2 PU-films that were composed of unmodified PU or PU surface modified with covalently appended human CD47 (hCD47) or bovine CD47 (bCD47) or a combination of the three films. Briefly, 300-350 g male Sprague-Dawley rats were anesthetized with isoflurane and administered Flunixamine post surgery for analgesia. PU implants were placed into individually dissected dorsal subdermal pouches. Animals were fed normal Purina Rat Chow ad libitum for the duration of the study. At the 70-day termination of the study, rats were euthanized by carbon dioxide asphyxiation and the subdermal implants were removed, rinsed briefly with saline and further processed as detailed below.
The rats tolerated the 10 week polyurethane (PU) subdermal implants and showed no evidence of morbidity or infection. Upon explantation all samples were readily identified and processed for assessment of evidence of oxidative related degradation. Shown in
Explanted films were decellularized and assessed, via FTIR, for evidence of oxidative degradation. It has been well documented that oxidation of polyurethane elastomers corresponds with an increase in peak intensity at 1174 cm−1 spectral peak (Stachelek, S J et al. (2006) J. Biomed. Mater. Res. A. 78:653-61). The 1174 cm−1 is assigned to the ν(C—O—C) of branched ether, which has been identified as a marker of oxidative degradation, and the extent of ether cross-linking can be quantitatively determined by normalizing the 1174 cm−1 spectral peak intensity with the peak intensity of the 1595 cm−1 spectral peak. The 1595 cm−1 peak corresponds to a non-oxidized aromatic ring. Shown in
Scanning electron micrographs of the explanted films (
The Chandler loop was used to compare the effects of the CD47 modified polyvinyl chloride (PVC) surfaces with PVC tubing either unmodified or modified with poly(2-methoxyethyl acrylate) (PMEA) (X Coating™ from Terumo) on whole blood cellular attachment under flow conditions using the protocol described in Example 5.
Various terms relating to the systems, methods, and other aspects of the present invention are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art unless otherwise indicated.
The present invention is not limited to the embodiments described and exemplified above, but is capable of variation and modification within the scope and range of equivalents of the appended claims.
This application claims priority under 35 U.S.C. §119 to U.S. Provisional Application No. 61/248,618, filed on Oct. 5, 2009, and U.S. Provisional Application No. 61/167,991, filed on Apr. 9, 2009, the contents of both of which are incorporated by reference herein, in their entirety and for all purposes.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US10/30558 | 4/9/2010 | WO | 00 | 5/7/2012 |
| Number | Date | Country | |
|---|---|---|---|
| 61167991 | Apr 2009 | US | |
| 61248618 | Oct 2009 | US |
